Tanvetyanon, Tawee

Smoking cessation, version 1.2016, NCCN clinical practice guidelines in oncology

Shields, P. G., Herbst, R. S., Arenberg, D., Benowitz, N. L., Bierut, L., Luckart, J. B., Cinciripini, P., Collins, B., David, S., Davis, J., et al. (2016) · Journal of the National Comprehensive Cancer Network

Smoking Behavior and CessationLung Cancer Diagnosis and Treatment

Cited by 146

Beta‐carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: A meta‐analysis and evaluation of national brands

Tanvetyanon, T., & Bepler, G. (2008) · Cancer

Antioxidant Activity and Oxidative StressLung Cancer Diagnosis and Treatment

Cited by 122

Variance of SUVs for FDG-PET/CT is Greater in Clinical Practice Than Under Ideal Study Settings

Kumar, V., Nath, K., Berman, C. G., Kim, J., Tanvetyanon, T., Chiappori, A. A., Gatenby, R. A., Gillies, R. J., & Eikman, E. A. (2013) · Clinical Nuclear Medicine

Medical Imaging Techniques and ApplicationsRadiomics and Machine Learning in Medical Imaging

Cited by 76

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer

Chiappori, A. A., Williams, C. C., Gray, J. E., Tanvetyanon, T., Haura, E. B., Creelan, B. C., Thapa, R., Chen, D.-T., Simon, G. R., Bepler, G., et al. (2019) · Cancer Immunology, Immunotherapy

Immunotherapy and Immune ResponsesLung Cancer Research Studies

Cited by 64

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.

Saltos, A. N., Tanvetyanon, T., Creelan, B. C., Shafique, M. R., Antonia, S. J., Haura, E. B., Zheng, H., Yu, X., Saller, J. J., Viracacha, S., et al. (2023) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 9